Trial Profile
Open, randomized and multicenter phase IV study to compare the efficacy and safety of two different treatments duration 24 versus 48 weeks in chronic hepatitis C genotypes 2 and/or 3 co-infected HIV-HCV [hepatitis C virus] patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms KHRONOS
- 15 Mar 2008 New trial record.